The long-term objective is to examine HIV evolution and immune function in HIV-infected children and adolescents who, following initiation of protease inhibitor containing antiretroviral therapy [ART], reconstitute immunity [Immune success, IS] but fail to control viral replication [viral failure, VF]. Studies will focus on a unique cohort of treated patients who have sustained immune reconstitution in spite of viral loads that would predict disease progression. This outcome group presents a novel paradigm for the investigation of virus/host cell interactions that are likely to lead to novel new therapeutic strategies. The hypothesis underlying the proposal is that ART-induced discordant responses is multifactorial, involving phenotypic properties of the virus, functional integrity of the thymus, and the impact of ongoing viral replication on immunity. To determine the mechanisms involved in VF/IS responses, three specific aims are proposed:
Specific Aim 1. To examine the evolutionary dynamics of amino acid substitutions in Gag and protease [PR] within the peripheral blood compartments of VF/IS individuals. Accumulation and modulation of genetic markers in Gag and PR amino acid sequences that develop in VF/IS individual during ART will be used to evaluate: [A.] compartmentalization of viruses in plasma and in CD4 CD45RO T lymphocytes and [B.] reservoirs of virus in CD4 CD45RA T lymphocytes.
Specific Aim 2. To identify genetic determinants in gag and PR from VF/IS individuals that contribute preferentially to restricted replication in thymocytes. Recombinant viruses with gag/PR regions derived from discordant patients will be constructed and evaluated in culture to: [A.] compare pre- and post therapy gag/PR regions from viruses from VF/IS individuals with respect to their capacity to replicate in thymocytes and PBMC ex vivo and [B.]map genetic determinants in Gag and PR that contribute to preferential restriction of replicative capacity in thymocytes.
Specific Aim 3. To determine the impact of ongoing viral replication on immunity among individuals who have discordant viral and immune outcomes. Specific studies will evaluate: [A.] thymic output, [B.] post thymic T cell activation and differentiation, and [C.] functional immune response to neoantigen between VS/IS and VF/IS outcome groups.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI047723-08
Application #
7763906
Study Section
Special Emphasis Panel (ZRG1-AARR-C (02))
Program Officer
Salzwedel, Karl D
Project Start
2001-04-15
Project End
2012-01-31
Budget Start
2010-02-01
Budget End
2012-01-31
Support Year
8
Fiscal Year
2010
Total Cost
$447,567
Indirect Cost
Name
University of South Florida
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
069687242
City
Tampa
State
FL
Country
United States
Zip Code
33612
Syed, Salma S; Balluz, Rula S; Kabagambe, Edmond K et al. (2013) Assessment of biomarkers of cardiovascular risk among HIV type 1-infected adolescents: role of soluble vascular cell adhesion molecule as an early indicator of endothelial inflammation. AIDS Res Hum Retroviruses 29:493-500
Yin, Li; Liu, Li; Sun, Yijun et al. (2012) High-resolution deep sequencing reveals biodiversity, population structure, and persistence of HIV-1 quasispecies within host ecosystems. Retrovirology 9:108
Wallet, Mark A; Reist, Caroline M; Williams, Julie C et al. (2012) The HIV-1 protease inhibitor nelfinavir activates PP2 and inhibits MAPK signaling in macrophages: a pathway to reduce inflammation. J Leukoc Biol 92:795-805
Haraguchi, Soichi; Ho, Sarah K; Morrow, Matthew et al. (2011) Developmental regulation of P-glycoprotein activity within thymocytes results in increased anti-HIV protease inhibitor activity. J Leukoc Biol 90:653-60
Brown, Joseph; Wallet, Mark A; Krastins, Bryan et al. (2010) Proteome bioprofiles distinguish between M1 priming and activation states in human macrophages. J Leukoc Biol 87:655-62
Wallet, Mark A; Rodriguez, Carina A; Yin, Li et al. (2010) Microbial translocation induces persistent macrophage activation unrelated to HIV-1 levels or T-cell activation following therapy. AIDS 24:1281-90
Rudy, Bret J; Sleasman, John; Kapogiannis, Bill et al. (2009) Short-cycle therapy in adolescents after continuous therapy with established viral suppression: the impact on viral load suppression. AIDS Res Hum Retroviruses 25:555-61
Yin, Li; Kou, Zhong Chen; Rodriguez, Carina et al. (2009) Antiretroviral therapy restores diversity in the T-cell receptor Vbeta repertoire of CD4 T-cell subpopulations among human immunodeficiency virus type 1-infected children and adolescents. Clin Vaccine Immunol 16:1293-301
Sleasman, J W; Robbins, B L; Cross, S J et al. (2009) Abacavir pharmacokinetics during chronic therapy in HIV-1-infected adolescents and young adults. Clin Pharmacol Ther 85:394-401
Ho, Sarah K; Perez, Elena E; Rose, Stephanie L et al. (2009) Genetic determinants in HIV-1 Gag and Env V3 are related to viral response to combination antiretroviral therapy with a protease inhibitor. AIDS 23:1631-40

Showing the most recent 10 out of 35 publications